TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria~* Males and females, 18 to 77 years old, with type 2 diabetes and inadequate glycemic control~* Participants who have been receiving metformin at a total daily dose ≥1500 mg per day for at least 8 weeks~* C-peptide ≥1.0 ng/mL~* Body mass index ≤45.0 kg/m\^2~* Serum creatinine level \<1.50 mg/dL for men or \<1.40 mg/dL for women.~Key Exclusion Criteria~* Aspartate aminotransferase and/or alanine aminotransferase level \>3.0 times the upper limit of normal~* Serum total bilirubin level \>2 mg/dL~* Creatinine kinase level \>3 times upper limit of normal~* Symptoms of severely uncontrolled diabetes~* Serum creatinine level ≥1.50 mg/dL for men or ≥1.40 mg/dL for women~* Currently unstable or serious cardiovascular, renal, hepatic, hematologic, oncologic, endocrine, psychiatric, or rheumatic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Placebo + Metformin (Type: PLACEBO_COMPARATOR): Participants received dapagliflozin-matching placebo once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
- Dapagliflozin, 2.5 mg + Metformin (Type: EXPERIMENTAL): Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
- Dapagliflozin, 5 mg + Metformin (Type: EXPERIMENTAL): Participants received dapagliflozin, 5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
- Dapagliflozin, 10 mg + Metformin (Type: EXPERIMENTAL): Participants received dapagliflozin, 10 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have been meeting the diagnostic criteria for binge eating disorder (according to the Diagnostic and Statistical Manual for Mental Disorders - IV Edition criteria) with at least 2 days of binge eating per week and severity at least moderate defined by binge eating scale (score = 17)~* BMI = \> 30 kg/m2 to \< 46 kg/m2~* Women must be post menopausal for at least one year or surgically sterilized (hysterectomy, tubal ligation), or practice sexual abstinence or use an acceptable method of birth control (i.e. a hormonal contraceptive, spermicide plus barrier method, intrauterine device and/or vasectomized partner)~Exclusion Criteria:~* Has a history or actual diagnostic of significant psychiatric disorder (schizophrenia, psychosis, major affective disorder, suicide risk, dementia, abuses alcohol or other drugs)~* has a malignancy or a history of malignancy within the past 5 years (except basal cell carcinoma)~* evidence of uncontrolled thyroid disorders~* uncontrolled hypertension (defined as a diastolic blood pressure \>110 mm/Hg and/or a systolic blood pressure \>180 mm/Hg with or without medication). Hypertensive patients on medications must have been on the same dose of the same antihypertensive medication for at least two months~* history or significant renal failure or glaucoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults aged 19 years or older.~* The subjects who give written consent to participate in the study voluntarily and are able to comply with all study requirements.~* If female and capable of bearing children,subject has a negative urine pregnancy test result on screening and agrees to employ adequate birth control measures through the study period.~Exclusion Criteria:~* Subjects who are hypersensitive to any component of vaccine, i.e., eggs, chicken or chicken products.~* Subjects with immune deficiency disorder.~* History of Guillain-Barre syndrome.~* Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination.~* Subjects who experienced fever within 24 hours before vaccination or with the febrile disease(exceeding 38.0℃) on screening day or with any acute respiratory infection.~* Subjects who had received immunosuppressant or immune-modifying drug within 3 months before screening.~* Subjects who had received blood products or immunoglobulin within 3 months before screening.~* Subjects who had received influenza vaccination within 6 months prior to the screening.~* Subjects who had received other vaccination within a month before screening, or those who had another vaccination scheduled within a month after study vaccination.~* Subjects who had participated in other clinical trial within 4 weeks prior to study vaccination.~* Subjects who had done blood donation within a week prior to study vaccination or planned blood donation within 7 months after study vaccination.~* Subjects with clinically significant chronic disease or malignant cancer.~* Pregnant women, breast-feeding women.~* Any other condition which, in the opinion of the Investigator, prevents the subject from participating in the study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- NBP607 (Type: EXPERIMENTAL): cell culture-derived trivalent inactivated subunit influenza vaccine
- Agrippal S1 (Type: ACTIVE_COMPARATOR): egg-derived trivalent inactivated subunit influenza vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ibuprofen Alone and in Combination With Acetaminophen for Treatment of Fever

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 months - 7 years of age at time of the fever.~* Initial temperature of 38.0C (100.4F) or more.~* Ability to cooperate with serial temporal artery temperature measurements.~* Ability to take medications by mouth.~* Willingness of the child's guardian/sponsor to give informed consent~Exclusion Criteria:~* Patients who have received acetaminophen within 6 hours of presentation, or ibuprofen, aspirin, or other non-steroidal anti-inflammatory medications within 8 hours of presentation.~* Patients \>=3 years of age that have received narcotics in the previous 24 hours.~* Children with weight \>60 kg. Treatment of children with weights \>60 kg will result in greater than recommended adult doses of the medications.~* History of adverse reaction to any study medication ingredient.~* History of diabetes mellitis, renal dysfunction, hepatic dysfunction, or thrombocytopenia.~* Presence of moderate or severe dehydration.~* Inclusion in the trial on 3 previous occasions~* Medical judgment that the severity of the underlying illness prohibits inclusion.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 7 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: ACTIVE_COMPARATOR): At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg)
- B (Type: EXPERIMENTAL): At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) and an appropriate dose of Acetaminophen (15 mg/kg)
- C (Type: EXPERIMENTAL): At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) and at time 3 hours is given an appropriate dose of Acetaminophen (15 mg/kg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Device to Reduce Surgery Site Contamination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Candidate for primary total hip arthroplasty~Exclusion Criteria:~* Prior history of infection~* Revision arthroplasty~* Screens positive for MRSA~* Undergoing hemiarthroplasty or resurfacing

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No device used (Type: NO_INTERVENTION): None
- Device attached, not activated (Type: SHAM_COMPARATOR): None
- Device deployed and activated (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Male gender~2. Age ≥18 years and ≤45 years~3. BMI ≥16~4. P. falciparum parasitaemia at any density~5. G6PD deficiency by Beutler Fluorescent Spot test for intervention groups and control group receiving AL only (N=50)~6. G6PD normal activity by Beutler Fluorescent Spot test for control groups (N=20)~7. Informed consent by participant~Exclusion Criteria:~1. Enrolled in another clinical trial~2. Fever \>37.5°C (tympanic) or history of fever in the last 24 hours~3. Evidence of severe illness / danger signs or active infection other than malaria~4. Known allergy to study medications~5. Hb \<11 g/dL~6. Antimalarials taken within the last 2 weeks~7. PQ taken within the last 4 weeks and blood transfusion within the last 90 days~8. Non-falciparum malaria co-infection~9. Current use of tuberculosis or anti-retroviral medication, sulphonamides, dapsone, nitrofurantoin, , nalidixic acid, ciprofloxacin, , methylene blue, toluidine blue phenazopyridine and co-trimoxazole.~10. History of severe chronic illness

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- G6PD deficient 0.25 mg/kg PQ + AL (Type: EXPERIMENTAL): G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
- G6PD deficient receiving AL only (Type: ACTIVE_COMPARATOR): G6PD deficient males receiving Artemether-Lumefantrine (AL) combination
- G6PD normal 0.25 mg/kg PQ + AL (Type: ACTIVE_COMPARATOR): G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
- G6PD normal 0.4 mg/kg PQ + AL (Type: ACTIVE_COMPARATOR): G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
- G6PD-deficient 0.4 mg/kg PQ + AL (Type: EXPERIMENTAL): G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Octanoic Acid for Treatment of Essential Voice Tremor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants have a diagnosis of essential voice tremor and show signs of tremor during the endoscopy examination (when pictures of the voice box are obtained)during screening appointment~* Participants show measurable voice tremor from recordings of the voice during screening appointment~Exclusion Criteria:~* Participants have a diagnosis or show signs of Parkinson's Disease or another non-essential tremor movement disorder~* Participants have a diagnosis or show signs of spasmodic dysphonia (a different neurological voice disorder)~* Participants have a diagnosis of a severe, non-stable medical condition, such as kidney or liver failure, severe heart disease, severe lung disease, severe metabolic disease, uncontrolled hyperthyroidism, or other life-threatening disease such as active cancer~* Participants have a diagnosis of diabetes mellitus~* Participants are unable to suspend/stop a medication that they are currently taking for tremor or voice disorder for 12 weeks to complete this study~* Participants have a dependence on alcohol or allergy to alcohol~* Participants are pregnant or lactating~* Participants have an allergy to soy~* Participants have Irritable Bowel Syndrome

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inactive capsule (Type: PLACEBO_COMPARATOR): Participants will receive a pill/capsule with an inactive ingredient during the placebo arm of this study.
- Octanoic acid (Type: EXPERIMENTAL): Participants will receive a pill/capsule with octanoic acid (amount determined by the participant's weight) during the experimental arm of this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HALT Progression of Polycystic Kidney Disease Study A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ADPKD.~* Age 15-49 (Study A); Age 18-64 (Study B).~* GFR \>60 mL/min/1.73 m2 (Study A); GFR 25-60 mL/min/1.73 m2 (Study B).~* BP ≥130/80 or receiving treatment for hypertension.~* Informed Consent.~Exclusion Criteria:~* Pregnant/intention to become pregnant in 4-6 yrs.~* Documented renal vascular disease.~* Spot urine albumin-to-creatinine ratio of \>0.5 (Study A) or ≥1.0 (Study B) and/or findings suggestive of kidney disease other than ADPKD.~* Diabetes requiring insulin or oral hypoglycemic agents / fasting serum glucose of \>126 mg/dl / random non-fasting glucose of \>200 mg/dl.~* Serum potassium \>5.5 milliequivalent per liter (mEq/L) for participants currently on ACE-I or ARB; \>5.0 mEq/L for participants not currently on ACE-I or ARB.~* History of angioneurotic edema or other absolute contraindication for ACE-I or ARB. Intolerable cough associated with ACE-I is defined as a cough developing within six months of initiation of ACE-I in the absence of other causes and resolving upon discontinuation of the ACE-I.~* Indication (other than hypertension) for β-blocker or calcium channel blocker therapy (e.g. angina, past myocardial infarction, arrhythmia), unless approved by the site principal investigator. (PI may choose to accept an individual who is on only a small dose of one of these agents and would otherwise be eligible.)~* Systemic illness necessitating nonsteroidal antiinflammatory drugs (NSAIDs), immunosuppressant or immunomodulatory medications.~* Systemic illness with renal involvement.~* Hospitalized for acute illness in past 2 months.~* Life expectancy \<2 years.~* History of non-compliance.~* Unclipped cerebral aneurysm \>7mm diameter.~* Creatine supplements within 3 months of screening visit.~* Congenital absence of a kidney (also total nephrectomy for Study B).~* Known allergy to sorbitol or sodium polystyrene sulfonate.~* Exclusions specific to magnetic resonance imaging (Study A).

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Study A, Arm 1 (Type: ACTIVE_COMPARATOR): Lisinopril + Telmisartan (ACE-I + ARB) and standard blood pressure control of 120-130/70-80 mm Hg
- Study A, Arm 2 (Type: ACTIVE_COMPARATOR): Lisinopril + Telmisartan (ACE-I + ARB) and low blood pressure control of 95-110/60-75 mm Hg
- Study A, Arm 3 (Type: PLACEBO_COMPARATOR): Lisinopril + Placebo (ACE-I + Placebo) and standard blood pressure control of 120-130/70-80 mm Hg
- Study A, Arm 4 (Type: PLACEBO_COMPARATOR): Lisinopril + Placebo (ACE-I + Placebo) and low blood pressure control of 95-110/60-75 mm Hg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Rosuvastatin on Cytokines After Traumatic Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Man or woman \> 16 and \< 60 years old with HI less 24 hours in progression and Glasgow between \< 13~* Acceptance of family to participate (first grade)~Exclusion Criteria:~* Previous head injury with severe disability~* History of neurological or psychiatric disease with severe disability~* Administration 24 hrs previous of: fibrates, niacin, ciclosporin, azoles, macrolides, inhibitors of protease, nefazodone, verapamil, diltiazem,amiodarone~* Very poor possibilities for survival~* Use of Administration of THAM, mannitol, barbiturates, corticosteroids, scavengers of free radicals, inhibitors of lipidic peroxidation, indometacin, calcium antagonist, antagonists of neurotransmitters before randomization~* isolated lesions in brain stem~* Allergy to the drug~* Hepatopathy or myopathy (or) history of this, or clinical data of hepatic disease~* Management previous in other Hospital~* Pregnancy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin (Type: EXPERIMENTAL): 20 mg oral during 10 days
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18-60 years of age~* Pre-bronchodilatory FEV1 ≥70% of predicted normal allergic asthmatic with a history of episodic wheeze~* Positive allergen induced early and late airway bronchoconstriction showing ≥ 20% fall in FEV1 for the early and ≥ 15% for the late response~* Positive skin prick test to common aeroallergens~Exclusion Criteria:~* Any clinically significant disease or disorder~* Any clinically relevant abnormal finding at screening examinations~* Smoker or ex-smoker who has stopped smoking \< 12 months prior to study start~* Worsening of asthma or respiratory infection within 6 weeks from visit 1~* Allergen-specific immunotherapy within 6 months prior to visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD5423 75ug
- 2 (Type: EXPERIMENTAL): AZD5423 300ug
- 3 (Type: ACTIVE_COMPARATOR): Budesonide 200 microgram
- 4 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Miltefosine in Children and Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 2-12 years of age, or 18-60 years of age~* Weight greater than 10 kg~* Parasitologic confirmation of cutaneous leishmaniasis~* Normal hepatic and kidney function~Exclusion Criteria:~* Pregnant or lactating women, and women who are planning to conceive during the study or that reject the use of birth control methods.~* Use of drugs with antileishmanial potential during the previous 6 months, including pentavalent antimonials, amphotericin B, miltefosine, and pentamidine~* Mucocutaneous or visceral leishmaniasis~* For female children, menses or other evidence of reproductive maturity

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Miltefosine (Type: EXPERIMENTAL): Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete